PTC
ALNY icon

Private Trust Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Private Trust Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.8K Buy
79
+23
+41% +$6.94K ﹤0.01% 1712
2026
Q1 		$18.5K Buy
56
+28
+100% +$9.53K ﹤0.01% 1724
2025
Q4 		$11.1K Sell
28
-547
-95% -$242K ﹤0.01% 1896
2025
Q3 		$262K Buy
575
+543
+1,697% +$221K 0.02% 643
2025
Q2 		$10.4K Buy
+32
New +$8.86K ﹤0.01% 1803
2024
Q4 		– Sell
-3
Closed -$825 – 2327
2024
Q3 		$825 Buy
+3
New +$781 ﹤0.01% 2216
2023
Q2 		– Sell
-1
Closed -$200 – 2286
2023
Q1 		$200 Hold
1
– – ﹤0.01% 2240
2022
Q4 		$0 Hold
1
– – ﹤0.01% 2164
2022
Q3 		$0 Hold
1
– – ﹤0.01% 2015
2022
Q2 		$0 Buy
+1
New +$142 ﹤0.01% 2090
2014
Q2 		– Sell
-6
Closed – – 1940
2014
Q1 		$0 Sell
6
-2
-25% -$155 ﹤0.01% 1820
2013
Q4 		$1K Buy
+8
New +$477 ﹤0.01% 1602

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Trust Company's ALNY Position: Q2 2026 in Review

Private Trust Company increased its Alnylam Pharmaceuticals (ALNY) stake by 41% in Q2 2026, buying an estimated $6.94K and bringing the position to 79 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1712.

Private Trust Company first reported a position in ALNY in Q4 2013 and has held it in 12 quarters since. The position peaked at $262K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Private Trust Company held 79 shares of Alnylam Pharmaceuticals worth $23.8K as of Q2 2026.
  • Private Trust Company bought 23 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.94K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #1712 holding.
  • Private Trust Company first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 12 quarters since.
  • Private Trust Company's Alnylam Pharmaceuticals position peaked at $262K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.